REFERENCE
Perrocheau G, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, Faroux R, Douillard JY, Pacull A.Cost-minimization analysis of capecitabine + oxaliplatin (Xelox) vs. infusional 5-FU/LV + oxaliplatin (Folfox-6) as first-line treatment for metastatic colorectal cancer in the French setting. Value in Health 10: A233 (plus oral presentation) abstr. EC3, No. 6, Nov-Dec 2007
Rights and permissions
About this article
Cite this article
XELOX cost saving versus FOLFOX-6 in MCRC. Pharmacoecon. Outcomes News 541, 9 (2007). https://doi.org/10.2165/00151234-200705410-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705410-00014